Beclometasone/formoterol/glycopyrronium prescribing across the NHS.
This is England's biggest triple-therapy inhaler, running at about 325,000 items and £16m at list price a month for COPD and, increasingly, severe asthma. Its headline year-on-year growth is mostly a coding artefact; the line only took its current shape during 2025, when triple products received their own BNF codes.
The NHS in England dispensed 3,831,884 prescription items of Beclometasone/formoterol/glycopyrronium in the 12 months to July 2026, across primary care and hospitals.
Spending on Beclometasone/formoterol/glycopyrronium over those 12 months was £187.5m at net ingredient cost, the list price of what was dispensed before any discounts.
We do not publish a year-on-year change for Beclometasone/formoterol/glycopyrronium. Triple-therapy inhalers were given their own BNF codes during 2025, so a year-on-year figure here measures the recoding, not prescribing.
100% of Beclometasone/formoterol/glycopyrronium volume moved through primary care and 0% through hospital pharmacies.
Beclometasone/formoterol/glycopyrronium ranks #3 of 12 chemical substances in Corticosteroids (respiratory) (BNF 3.2), by items dispensed.
Among Integrated Care Boards, NHS North East and North Cumbria ICB dispensed the highest volume of Beclometasone/formoterol/glycopyrronium.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 350,473 | £17.2m |
| June 2026 | 333,562 | £16.3m |
| May 2026 | 317,279 | £15.5m |
| April 2026 | 324,764 | £15.9m |
| March 2026 | 327,930 | £16.1m |
| February 2026 | 297,937 | £14.6m |
| January 2026 | 322,214 | £15.8m |
| December 2025 | 335,324 | £16.4m |
| November 2025 | 297,601 | £14.6m |
| October 2025 | 322,584 | £15.8m |
| September 2025 | 309,488 | £15.1m |
| August 2025 | 292,728 | £14.3m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
15.0% of its class.
Beclometasone/formoterol/glycopyrronium ranks #3 of 12 chemical substances in Corticosteroids (respiratory) (BNF 3.2), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
Beclometasone/formoterol/glycopyrronium across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much beclometasone/formoterol/glycopyrronium its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Beclometasone/formoterol/glycopyrronium is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS North East and North Cumbria ICB 301k
- 2 NHS Cheshire and Merseyside ICB 266k
- 3 NHS Greater Manchester ICB 232k
- – + 33 more. See the full 36-ICB table. See all →
Not shown for beclometasone/formoterol/glycopyrronium. Triple-therapy inhalers were given their own BNF codes during 2025, so a year-on-year figure here measures the recoding, not prescribing. Every ICB is measured against that same broken year, so a growth ranking would rank the recoding rather than the prescribing. Volume, in the list beside this one, is unaffected.
- 1 Trimbow 87microg/dose / 5microg/dose / 9microg/dose inh 66%
- 2 Trimbow 172microg/dose / 5microg/dose / 9microg/dose inh 17%
- 3 Trimbow NEXThaler 88microg/5microg/9microg/dose dry pdr inh 17%
- – + 3 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 3.8m | July 2026 |
| Scotland | 300k | June 2026 |
| Northern Ireland | 113k | May 2026 |
| Wales | 0 | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about beclometasone/formoterol/glycopyrronium.
We could quote a spectacular growth figure for this line. It would be false. The genuine signals are the steady monthly run-rate and the strong skew toward England's most deprived areas, where COPD lives.
Asked and answered.
Is beclometasone/formoterol/glycopyrronium prescribing rising or falling in the NHS?
We cannot answer that honestly for beclometasone/formoterol/glycopyrronium yet. Triple-therapy inhalers were given their own BNF codes during 2025, so a year-on-year figure here measures the recoding, not prescribing. England dispensed 3,831,884 items in the 12 months to July 2026, and the monthly run-rate on this page is the figure to read instead.
How much does the NHS spend on beclometasone/formoterol/glycopyrronium?
£187.5m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is beclometasone/formoterol/glycopyrronium prescribed most?
By raw volume, NHS North East and North Cumbria ICB dispensed the most beclometasone/formoterol/glycopyrronium in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track beclometasone/formoterol/glycopyrronium like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Beclometasone/formoterol/glycopyrronium for you.